Hukumar kula da abinci da magunguna wato Food and Drug Administration (FDA), wacce ta kasance hukumar kasar Amurka na lafiya da jama’a, ta amince da Crizanlizumab-tmca, wani sabon maganin cutar sikila mai tsanani.
An amince da sabon maganin, wanda irin shi ne na farko da aka tanadar domin cutar, a ranar Juma’a, yayinda FDA ta ba Novartis, wani kamfanin hada magunguna daban-daban, goyon bayan siyar da Adakveo, a kasar.
An tanadi Adakveo ne domin rage radadin cutar da ke faruwa a lokacin da jinin sikila ya hana gudanar jini a jikin marasa lafiya daga shekara 16 da sama da haka.
A cewar hukumar FDA, an amince da maganin ne bayan gwada shi da aka yi kan masu fama da cutar sikila 198 wanda ke fama da radadin na of vaso-occlusive, inda wadanda suka samu Adakveo a madadin placebo suka rage ziyartan cibiyar kiwon lafiya.
Da yake magana a taron amincewa da maganin, Brett Giroir, mukaddashin kwamishinan FDA, ya ce damar da ake samu a tsakanin kwararrun likitoci da ke aiki domin warkar da mutanen da ke dauke da cutar sikila a yan watanni da shekaru masu zuwa ya kasance bayananne kuma mai dumbin tarihi.
A SCD, siffar kwayar halittar jini bai kasancewa daidai sannan hakan na hana jini yawo yadda ya kamata, yana takaita isar da iskar da dan adam ke shaka wato Oxygen zuwa tsokar jiki, sannan hakan kan haifar da radadi sosai da lalata sashin jiki.
A cewar Richard Pazdur, daraktan cibiyar FDA, Adakveo zai rage yawan kwantar da marasa lafiya a asibiti akai-akai.
Akalla Amurkawa 100,000 ne ke fama da cutar sikila, a cewar cibiyar kula da cututtuka da daukat mataki wato Center for Disease Control and Prevention (CDC
Tags:
Cuta da Magani